Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 9, 2004BloodOpen Access

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

AFAndres ForeroHospital Militar CentralPWPaul L. WeidenUniversity of Southern CaliforniaJVJulie M. VoseNorthwestern University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Forero et al. (2004) studied this question.

synapsesocial.com/papers/6a7fbe957a7d14b22d9fe87fhttps://doi.org/10.1182/blood-2003-09-3284
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue.1998 · 289 citations
  2. 2A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts2001 · 149 citations